Forbes senior editor covering healthcare. Email [email protected], signal amyfeldman.33
Amy Feldman
Loading...
👀👀👀
During the reporting @forbes.com also learned that Chai is in talks to raise $400M more VC funding at a $3.4B valuation.
Really sad to see this. RIP
www.npr.org/2026/06/04/n...
“The models were smoke and mirrors for a long time. We knew we had to make things literally 100 times better for it to be valuable for real drug discovery programs,” says Chai cofounder Jack Dent
With thanks to @rashis.bsky.social for additional reporting
It quietly released its latest model Chai-3 earlier this year, and its founders now tell us exclusively they’ve signed a 2nd big pharma deal, with Pfizer, just 5 months after doing so with Lilly.
Amy Feldman
My latest @forbes.com feature looks at Chai Discovery, the buzzy AI drug discovery company worth $1.3B.
www.forbes.com/sites/amyfel...
Under Trump’s effort to control $$ for his political agenda, researchers who get fed grants wld face limits on the subjects they can explore, foreign labs they can collab with, etc.
It wld “devastate innov, science & research,” says public health advocacy group head
www.nytimes.com/2026/06/02/u...
AI startup Collate raises $95M to automate life sciences paperwork. Exclusively in @forbes.com InnovationRx newsletter. Plus: Clear’s move into healthcare, cancer breakthroughs from ASCO and more. With @thealexknapp.bsky.social
www.forbes.com/sites/innova...
One of the biggest misconceptions about Trump’s business is the idea that he put his assets into a blind trust—or gave them all away to his family members. He did neither.
Full PBS Newshour segment here: www.pbs.org/newshour/sho...
